Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulfiram
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Cantex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2020
Lead Product(s) : Sulfiram
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Cantex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfiram
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Repurposed Drug Helps Obese Mice Lose Weight, Improve Metabolic Function
Details : Treatment with disulfiram, normally prescribed to treat alcohol use disorder, shows health benefits in animal study.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Sulfiram
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulfiram
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co | The Alfred
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2017
Lead Product(s) : Sulfiram
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co | The Alfred
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2017